Cited by 1,012Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesCutaneous Melanoma Detection and Management

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4

Open access

Attia, Peter, Phan, Giao Q., Maker, Ajay V., Robinson, Michael R., Quezado, Martha M., Yang, James C., Sherry, Richard M., Topalian, Suzanne L., Kammula, Udai S., Royal, Richard E., Restifo, Nicholas P., Haworth, Leah R., Levy, Catherine, Mavroukakis, Sharon A., Nichol, Geoff, Yellin, Michael J., Rosenberg, Steven A.·2005·Journal of Clinical Oncology

DOI 10.1200/jco.2005.06.205PMC PMC1473965

Open this paper in CoChat — free account Open PDF

Abstract

Purpose: Previously, we reported our experience treating 14 patients with metastatic melanoma using a fully human antibody to cytotoxic T-lymphocyte antigen-4 (anti–CTLA-4) in conjunction with peptide vaccination. We have now treated 56 patients to evaluate two different dose schedules of anti–CTLA-4 and to explore the relationship between autoimmunity and tumor regression. Patients and Methods: A total of 56 patients with progressive stage IV melanoma were enrolled onto the study. All had Karnofsky performance status ≥ 60% with no prior history of autoimmunity. Twenty-nine patients received 3 mg/kg anti–CTLA-4 every 3 weeks, whereas 27 received 3 mg/kg as their initial dose with subsequent doses reduced to 1 mg/kg every 3 weeks. In both cohorts patients received concomitant vaccination with two modified HLA-A*0201-restricted peptides from the gp100 melanoma-associated antigen, gp100:209-217(210M) and gp100:280-288(288V). Results: Two patients achieved a complete response (ongoing at 30 and 31 months, respectively) and five patients achieved a partial response (durations of 4, 6, 25+, 26+, and 34+ months, respectively), for an overall objective response rate of 13%. Tumor regression was seen in lung, liver, brain, lymph nodes, and subcutaneous sites. Of 14 patients with grade 3/4 autoimmune toxicity, five (36%) experienced a clinical response compared with only two responses in the 42 patients (5%) with no autoimmune toxicity (P = .008). There were no significant differences in response rate or toxicity between the two dose schedules. Conclusion: Administration of anti–CTLA-4 monoclonal antibody plus peptide vaccination can cause durable objective responses, which correlate with the induction of autoimmunity, in patients with metastatic melanoma.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2005.06.205

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
Zhang, L., Xu, J., Zhang, X., Zhang, Y., Wang, L., Huang, X., & Xu, Z. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479442 · Cited by 4,090
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
An essential role for Scurfin in CD4+CD25+ T regulatory cells
Khattri, R., Cox, T., Yasayko, S.-A., & Ramsdell, F. (2003) · Nature Immunology · doi:10.1038/ni909 · Cited by 2,860
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
CD4+CD25+ suppressor T cells: more questions than answers
Shevach, E. M. (2002) · Nature reviews. Immunology · doi:10.1038/nri821 · Cited by 2,097

Flagged first, then by citations

Show all 44 references

Sorted by citations

Items 201–300 of 1,000

Interferon-γ Signaling in Melanocytes and Melanoma Cells Regulates Expression of CTLA-4
Mo, X., Zhang, H., Preston, S., Martin, K. A., Zhou, B., Vadalia, N., Gamero, A. M., Soboloff, J., Tempera, I., & Zaidi, M. R. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1615 · Cited by 125
Management of side effects of immune checkpoint blockade by anti‐CTLA‐4 and anti‐PD‐1 antibodies in metastatic melanoma
Kähler, K. C., Hassel, J. C., Heinzerling, L., Loquai, C., Mößner, R., Ugurel, S., Zimmer, L., & Gutzmer, R. (2016) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13047 · Cited by 120
Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs
Torino, F., Barnabei, A., Paragliola, R., Baldelli, R., Appetecchia, M., & Corsello, S. M. (2013) · Thyroid® · doi:10.1089/thy.2013.0241 · Cited by 117
Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
Day, D., & Hansen, A. R. (2016) · BioDrugs · doi:10.1007/s40259-016-0204-3 · Cited by 117
Pretreatment frequency of circulating IL‐17+CD4+ T‐cells, but not Tregs, correlates with clinical response to whole‐cell vaccination in prostate cancer patients
Derhovanessian, E., Adams, V., Hähnel, K., Groeger, A., Pandha, H., Ward, S., & Pawelec, G. (2009) · International Journal of Cancer · doi:10.1002/ijc.24497 · Cited by 122
ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses
Torino, F., Barnabei, A., Paragliola, R. M., Marchetti, P., Salvatori, R., & Corsello, S. M. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0434 · Cited by 117
Therapeutic use of anti-CTLA-4 antibodies
Blank, C. U., & Enk, A. (2014) · International Immunology · doi:10.1093/intimm/dxu076 · Cited by 115
Directions in the immune targeting of cancer: Lessons learned from the cancer‐testis Ag NY‐ESO‐1
Nicholaou, T., Ebert, L. M., Davis, I. D., Robson, N. C., Klein, O., Maraskovsky, E., Chen, W., & Cebon, J. S. (2006) · Immunology and Cell Biology · doi:10.1111/j.1440-1711.2006.01446.x · Cited by 112
Organizing Pneumonia as a Side Effect of Ipilimumab Treatment of Melanoma
Barjaktarević, I., Qadir, N., Suri, A., Santamauro, J. T., & Stover, D. E. (2013) · CHEST Journal · doi:10.1378/chest.12-1467 · Cited by 110
A Pilot Study of IL-2Rα Blockade during Lymphopenia Depletes Regulatory T-cells and Correlates with Enhanced Immunity in Patients with Glioblastoma
Sampson, J. H., Schmittling, R. J., Archer, G. E., Congdon, K. L., Nair, S. K., Reap, E. A., Desjardins, A., Friedman, A. H., Friedman, H. S., Herndon, J. E., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031046 · Cited by 109
Novel immune check point inhibiting antibodies in cancer therapy—Opportunities and challenges
Diesendruck, Y., & Benhar, I. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.02.001 · Cited by 107
Improving Antitumor Immune Responses by Circumventing Immunoregulatory Cells and Mechanisms
Lizee, G. A., Radvanyi, L. G., Overwijk, W. W., & Hwu, P. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0944 · Cited by 109
Treatment and side effect management of CTLA‐4 antibody therapy in metastatic melanoma
Kähler, K. C., & Hauschild, A. (2010) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2010.07568.x · Cited by 108
The Role of Tregs in Glioma-Mediated Immunosuppression: Potential Target for Intervention
Humphries, W. E., Wei, J., Sampson, J. H., & Heimberger, A. B. (2009) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2009.08.012 · Cited by 103
Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma: Natural Progression and Management
Huffman, B. M., Kottschade, L. A., Kamath, P. S., & Markovic, S. N. (2018) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000374 · Cited by 100
Autoimmune endocrine dysfunctions associated with cancer immunotherapies
Ferrari, S. M., Fallahi, P., Elia, G., Ragusa, F., Ruffilli, I., Patrizio, A., Galdiero, M. R., Baldini, E., Ulisse, S., Marone, G., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102560 · Cited by 107
Influence of Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA4) Common Polymorphisms on Outcome in Treatment of Melanoma Patients With CTLA-4 Blockade
Breunis, W. B., Tarazona‐Santos, E., Chen, R., Kiley, M., Rosenberg, S. A., & Chanock, S. J. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31817fd8f3 · Cited by 107
Self-citation
Out-of-Sequence Signal 3 Paralyzes Primary CD4+ T-Cell-Dependent Immunity
Sckisel, G. D., Bouchlaka, M. N., Monjazeb, A. M., Crittenden, M. R., Curti, B. D., Wilkins, D. E. C., Alderson, K. L., Sungur, C. M., Ames, E., Mirsoian, A., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.06.023 · Cited by 113
Clinical Impact of Checkpoint Inhibitors as Novel Cancer Therapies
Shih, K. C., Arkenau, H., & Infante, J. R. (2014) · Drugs · doi:10.1007/s40265-014-0305-6 · Cited by 109
Ipilimumab in the treatment of metastatic melanoma: management of adverse events
Scarpati, G. D. V., Fusciello, C., Perri, F., Sabbatino, F., Carlomagno, C., Pepe, S., & Ferrone, S. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s57335 · Cited by 106
The rapidly evolving therapies for advanced melanoma—Towards immunotherapy, molecular targeted therapy, and beyond
Zhu, Z., Liu, W., & Gotlieb, V. K. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.12.002 · Cited by 109
Ocular toxicities of MEK inhibitors and other targeted therapies
Stjepanovic, N., Velazquez-Martin, J. P., & Bedard, P. L. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw100 · Cited by 107
Immuno-oncology combinations: raising the tail of the survival curve
Harris, S. J., Harris, S. J., Brown, J. S., Lopez, J. S., Yap, T. A., Brown, J. S., Lopez, J. S., & Yap, T. A. (2016) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2016.0015 · Cited by 110
The role of interim 18F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma
Sachpekidis, C., Anwar, H., Winkler, J. K., Kopp‐Schneider, A., Larribère, L., Haberkorn, U., Hassel, J. C., & Dimitrakopoulou‐Strauss, A. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-3972-9 · Cited by 106
Gastrointestinal toxicity of immune checkpoint inhibitors: From mechanisms to management
Samaan, M. A., Pavlidis, P., Papa, S., Powell, N., & Irving, P. M. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2018.14 · Cited by 100
T-regulatory cell modulation: the future of cancer immunotherapy?
Nizar, S. A., Copier, J. P., Meyer, B., Bodman‐Smith, M. D., Galustian, C., Kumar, D., & Dalgleish, A. G. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605040 · Cited by 105
Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment
Lisi, L., Lacal, P. M., Martire, M., Navarra, P., & Graziani, G. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105997 · Cited by 106
Autoimmune Inflammatory Myopathy after Treatment with Ipilimumab
Hunter, G. R. W., Voll, C., & Robinson, C. A. (2009) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100007939 · Cited by 105
Pediatric Cancer Immunotherapy: Opportunities and Challenges
Wedekind, M. F., Denton, N. L., Chen, C., & Cripe, T. P. (2018) · Pediatric Drugs · doi:10.1007/s40272-018-0297-x · Cited by 113
Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies
Park, J. A., & Cheung, N. V. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.05.006 · Cited by 105
New insight in endocrine-related adverse events associated to immune checkpoint blockade
Elia, G., Ferrari, S. M., Galdiero, M. R., Ragusa, F., Paparo, S. R., Ruffilli, I., Varricchi, G., Fallahi, P., & Antonelli, A. (2019) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2019.101370 · Cited by 108
Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 with Ipilimumab (MDX-010)
Weber, J. S. (2008) · The Oncologist · doi:10.1634/theoncologist.13-s4-16 · Cited by 103
Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center
Lisberg, A. E., Tucker, D. A., Goldman, J. W., Wolf, B., Carroll, J., Hardy, A., Morris, K. K., Linares, P., Adame, C. R., Spiegel, M. L., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0063 · Cited by 102
GM-CSF Gene-Modifed Cancer Cell Immunotherapies: Of Mice and Men
Hege, K. M., Jooss, K. U., & Pardoll, D. M. (2006) · International Reviews of Immunology · doi:10.1080/08830180600992498 · Cited by 101
Melan-A–specific Cytotoxic T Cells Are Associated with Tumor Regression and Autoimmunity Following Treatment with Anti-CTLA-4
Klein, O., Ebert, L. M., Nicholaou, T., Browning, J., Russell, S. E., Zuber, M., Jackson, H. M., Dimopoulos, N., Tan, B. S., Hoos, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2424 · Cited by 100
Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer
Rahimian, S., Fransen, M. F., Kleinovink, J. W., Amidi, M., OSSENDORP, F. A., & Hennink, W. E. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.04.043 · Cited by 100
Strategies for improving the management of immune-related adverse events
Naing, A., Hajjar, J., Gulley, J. L., Atkins, M. B., Ciliberto, G., Meric‐Bernstam, F., & Hwu, P. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001754 · Cited by 99
Drug of the year: Programmed Death-1 receptor/Programmed Death-1 Ligand-1 receptor monoclonal antibodies
Robert, C., Soria, J., & Eggermont, A. M. M. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.07.001 · Cited by 95
Thyroid-Like Ophthalmopathy in a Euthyroid Patient Receiving Ipilimumab
McElnea, E., Ní Mhéalóid, Á., Moran, S., Kelly, R., & Fulcher, T. (2014) · Orbit · doi:10.3109/01676830.2014.949792 · Cited by 93
Stat3 as a Potential Target for Cancer Immunotherapy
Kortylewski, M., & Yu, H. (2007) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211327.76266.65 · Cited by 94
MANAGEMENT OF ENDOCRINE DISEASE: Immune check point inhibitors-induced hypophysitis
Albarel, F., Castinetti, F., & Brue, T. C. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0169 · Cited by 92
Phenotypical Analysis of Lymphocytes with Suppressive and Regulatory Properties (Tregs) and NK Cells in the Papillary Carcinoma of Thyroid
Gogali, F., Paterakis, G., Rassidakis, G. Z., Kaltsas, G., Liakou, C. I., Gousis, P., Neonakis, E., Manoussakis, M. N., & Liapi, C. A. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1838 · Cited by 92
The complex role of B7 molecules in tumor immunology
Seliger, B., Marincola, F. M., Ferrone, S., & Abken, H. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.09.010 · Cited by 93
T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment
Santegoets, S. J. A. M., Stam, A. G. M., Lougheed, S. M., Gall, H. E., Scholten, P. E. T., Reijm, M., Jooss, K. U., Sacks, N., Hege, K. M., Lowy, I., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1330-5 · Cited by 94
Vogt-Koyanagi-Harada-like Syndrome After CTLA-4 Inhibition With Ipilimumab for Metastatic Melanoma
Crosson, J. N., Laird, P. W., Debiec, M. R., Bergstrom, C. S., Lawson, D. H., & Yeh, S. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000066 · Cited by 91
Immunomodulatory therapy to preserve pancreatic β-cell function in type 1 diabetes
Waldron-Lynch, F., & Herold, K. C. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3402 · Cited by 96
New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies.
Azijli, K., Stelloo, E., Peters, G. J., & van den Eertwegh, A. J. M. (2014) · PubMed · Cited by 88
MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors
Marschner, D., Falk, M., Jávorniczky, N. R., Hanke, K., Rawluk, J. K., Schmitt-Graeff, A. H., Simonetta, F., Haring, E., Dicks, S., Ku, M., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.132334 · Cited by 90
Thermosensitive hydrogels as sustained drug delivery system for CTLA-4 checkpoint blocking antibodies
Chung, C. K., Fransen, M. F., van der Maaden, K., Campos, Y., García-Couce, J., Kralisch, D., Chan, A. B., OSSENDORP, F. A., & Cruz, L. J. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.03.050 · Cited by 90
Therapeutic Antibodies Against Cancer
Adler, M. J., & Dimitrov, D. S. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.02.013 · Cited by 94
Neutropenia in a Patient Treated With Ipilimumab (anti–CTLA-4 Antibody)
Akhtari, M., Waller, E. K., Jaye, D. L., Lawson, D. H., Ibrahim, R. A., Papadopoulos, N., & Arellano, M. L. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e31819aa40b · Cited by 89
HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activation
Rodríguez, J. A. (2017) · Oncology Letters · doi:10.3892/ol.2017.6784 · Cited by 93
From cancer immunosurveillance to cancer immunotherapy
Stagg, J., Johnstone, R. W., & Smyth, M. J. (2007) · Immunological Reviews · doi:10.1111/j.1600-065x.2007.00566.x · Cited by 91
Melanoma immunotherapy
Sanlorenzo, M., Vujic, I., Posch, C., Dajee, A., Yen, A., Kim, S. T., Ashworth, M. T., Rosenblum, M. D., Algazi, A. P., Osella‐Abate, S., et al. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.28555 · Cited by 94
Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo
Sandin, L. C., Eriksson, F., Ellmark, P., Loskog, A., Tötterman, T. H., & Mangsbo, S. M. (2014) · OncoImmunology · doi:10.4161/onci.27614 · Cited by 87
Anti-TNF-refractory colitis after checkpoint inhibitor therapy: Possible role of CMV-mediated immunopathogenesis
Lankes, K., Hundorfean, G., Harrer, T., Pommer, A. J., Agaimy, A., Angelovska, I., Tajmir-Riahi, A., Göhl, J., Schuler, G., Neurath, M. F., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1128611 · Cited by 85
New treatment options for metastatic renal cell carcinoma
Rodríguez‐Vida, A., Hutson, T. E., Joaquim Bellmunt, B., & Strijbos, M. H. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000185 · Cited by 89
Tumor Immunology and Immunotherapy of Non-Small-Cell Lung CancerPreprint
Cascone, T., Fradette, J. J., Pradhan, M., & Gibbons, D. L. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037895 · Cited by 91
Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases
Ibis, B., Aliazis, K., Cao, C., Yenyuwadee, S., & Boussiotis, V. A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1197364 · Cited by 92
Human Monoclonal Antibodies from Transgenic Mice
Lönberg, N. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-73259-4_4 · Cited by 90
Local targets for immune therapy to cancer: Tumor draining lymph nodes and tumor microenvironment
Fransen, M. F., Arens, R., & Melief, C. J. M. (2012) · International Journal of Cancer · doi:10.1002/ijc.27755 · Cited by 85
Regulatory T Cell–Resistant CD8+ T Cells Induced by Glucocorticoid-Induced Tumor Necrosis Factor Receptor Signaling
Nishikawa, H., Kato, T., Hirayama, M., Orito, Y., Sato, E., Harada, N., Gnjatic, S., Old, L. J., & Shiku, H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5839 · Cited by 84
Enhancing the clinical activity of granulocyte‐macrophage colony‐stimulating factor‐secreting tumor cell vaccines
Jinushi, M., Hodi, F. S., & Dranoff, G. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00618.x · Cited by 86
CTLA-4 blockade: therapeutic potential in cancer treatments
Tarhini, A. A. (2010) · OncoTargets and Therapy · doi:10.2147/ott.s4833 · Cited by 84
Therapeutic cancer vaccine: building the future from lessons of the past
Tran, T., Blanc, C., Granier, C., Saldmann, A., Tanchot, C., & Tartour, É. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0691-z · Cited by 85
Patient Responses to Ipilimumab, a Novel Immunopotentiator for Metastatic Melanoma
Pennock, G. K., Waterfield, W. C., & Wolchok, J. D. (2011) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e318209cda9 · Cited by 84
Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models
Shin, J. H., Park, H. B., Oh, Y. M., Lim, D. P., Lee, J. E., Seo, H. H., Lee, S. J., Eom, H., Kim, I.-H., Lee, S. H., et al. (2012) · Blood · doi:10.1182/blood-2011-09-380519 · Cited by 84
Cancer vaccines: on the threshold of success
Emens, L. A. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.13.2.295 · Cited by 83
Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities
Cousin, S., & Italiano, A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2569 · Cited by 83
Immune-mediated adverse events of anticytotoxic T lymphocyte–associated antigen 4 antibody therapy in metastatic melanoma
Quirk, S. K., Shure, A. K., & Agrawal, D. K. (2015) · Translational research · doi:10.1016/j.trsl.2015.06.005 · Cited by 82
Ipilimumab, Vemurafenib, Dabrafenib, and Trametinib: Synergistic Competitors in the Clinical Management of BRAF Mutant Malignant Melanoma
Luke, J. J., & Hodi, F. S. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0391 · Cited by 84
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma
Comı́n-Anduix, B., Lee, Y., Jalil, J., Algazi, A. P., de la Rocha, P., Camacho, L. H., Bozon, V. A., Bulanhagui, C. A., Seja, E., Villanueva, A., et al. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-22 · Cited by 82
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)
Giacomo, A. M. D., Danielli, R., Calabrò, L., Bertocci, E., Nannicini, C., Giannarelli, D., Balestrazzi, A., Vigni, F., Riversi, V., Miracco, C., et al. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0958-2 · Cited by 81
Safety and Efficacy of Therapeutic Cancer Vaccines Alone or in Combination With Immune Checkpoint Inhibitors in Cancer Treatment
Zhao, J., Chen, Y., Ding, Z., & Liu, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01184 · Cited by 80
Ipilimumab‐induced toxicities and the gastroenterologist
Cheng, R., Cooper, A. J., Kench, J. G., Watson, G., Bye, W. A., McNeil, C. M., & Shackel, N. A. (2015) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12888 · Cited by 81
Immunotherapy for Advanced Melanoma
Fang, L., Lonsdorf, A. S., & Hwang, S. T. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.101 · Cited by 85
CTLA-4 Is a Direct Target of Wnt/β-Catenin Signaling and Is Expressed in Human Melanoma Tumors
Shah, K. V., Chien, A. J., Yee, C., & Moon, R. T. (2008) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.170 · Cited by 84
Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era
Kalfeist, L., Galland, L., Ledys, F., Ghiringhelli, F., Limagne, E., & Ladoire, S. (2022) · Cells · doi:10.3390/cells11050770 · Cited by 78
Immunotherapy for Melanoma: Current Status and Perspectives
Alexandrescu, D. T., Ichim, T. E., Riordan, N. H., Marincola, F. M., Nardo, A. D., Kabigting, F. D., & Dasanu, C. A. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181e032e8 · Cited by 80
Immunity Feedback and Clinical Outcome in Colon Cancer Patients Undergoing Chemoimmunotherapy with Gemcitabine + FOLFOX followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Aldesleukin (GOLFIG-1 Trial)
Correale, P., Tagliaferri, P., Fioravanti, A., Vecchio, M. T. D., Remondo, C., Montagnani, F., Rotundo, M. S., Ginanneschi, C., Martellucci, I., Francini, E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5278 · Cited by 79
Hypophysitis Induced by Monoclonal Antibodies to Cytotoxic T Lymphocyte Antigen 4: Challenges from a New Cause of a Rare Disease
Torino, F., Barnabei, A., Vecchis, L. D., Salvatori, R., & Corsello, S. M. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0404 · Cited by 79
The role of regulatory T cells in the pathogenesis and treatment of prostate cancer
Karpisheh, V., Mousavi, S. M., Sheykholeslami, P. N., Fathi, M., Saray, M. M., Maleki, L. A., Jafari, R., Zolbanin, N. M., & Jadidi‐Niaragh, F. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119132 · Cited by 78
Enhancement of Dendritic Cells as Vaccines for Cancer
Turnis, M. E., & Rooney, C. M. (2010) · Immunotherapy · doi:10.2217/imt.10.56 · Cited by 79
Immune Checkpoint Inhibitors in Melanoma Provide the Cornerstones for Curative Therapies
Eggermont, A. M. M., Maio, M., & Robert, C. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.02.010 · Cited by 80
Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma
Gordon, I. O., Wade, T., Chin, K. M., Dickstein, J. I., & Gajewski, T. F. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0627-x · Cited by 77
Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist
Jamal, S., Hudson, M., Fifi-Mah, A. V., & Ye, C. (2019) · The Journal of Rheumatology · doi:10.3899/jrheum.190084 · Cited by 80
Combining Cancer Vaccines with Immunotherapy: Establishing a New Immunological Approach
Kim, C.-G., Sang, Y. B., Lee, J. H., & Chon, H. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158035 · Cited by 78
Ipilimumab and cancer immunotherapy: a new hope for advanced stage melanoma.
Mansh, M. D. (2011) · Europe PMC (PubMed Central) · Cited by 77
Immune-Related Adverse Events: Pneumonitis
Zhong, L., Altan, M., Shannon, V. R., & Sheshadri, A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-41008-7_13 · Cited by 80
Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma
Ng, K. Y. Y., Tan, S. H., Tan, J. J. E., Tay, D. S. H., Lee, A. W. X., Ang, A. J. S., Wong, L. W. J., Choo, S. P., Tai, D. W.-M., & Lee, J. J. X. (2021) · Liver Cancer · doi:10.1159/000518619 · Cited by 75
Ipilimumab: Unleashing the Power of the Immune System Through CTLA-4 Blockade
Boasberg, P. D., Hamid, O., & O'Day, S. J. (2010) · Seminars in Oncology · doi:10.1053/j.seminoncol.2010.09.004 · Cited by 73
Tremelimumab: A Review of Development to Date in Solid Tumors
Tarhini, A. A. (2013) · Immunotherapy · doi:10.2217/imt.13.9 · Cited by 74
Update on anti-CTLA-4 antibodies in clinical trials
Langer, L., Clay, T. M., & Morse, M. A. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.8.1245 · Cited by 73
Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette–Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma
Duarte, J. D. G., Parakh, S., Andrews, M. C., Woods, K., Pasam, A., Tutuka, C. S. A., Ostrouska, S., Blackburn, J. M., Behren, A., & Cebon, J. S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00411 · Cited by 75
Ipilimumab-induced hypophysitis: review of the literature
de Araújo, P. B., Coelho, M. C. A., Arruda, M., Gadelha, M. R., & Neto, L. V. (2015) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0301-z · Cited by 75
Are BiTEs the “missing link” in cancer therapy?
Suryadevara, C. M., Gedeon, P. C., Sanchez-Perez, L. A., Verla, T. G., Alvarez-Breckenridge, C. A., Choi, B. D., Fecci, P. E., & Sampson, J. H. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008339 · Cited by 72
Targeting the PD-1 pathway: a promising future for the treatment of melanoma
Mamalis, A., Garcha, M., & Jagdeo, J. R. (2014) · Archives of Dermatological Research · doi:10.1007/s00403-014-1457-7 · Cited by 74
Cancer Vaccines: Promising Therapeutics or an Unattainable Dream
Donninger, H., Li, C., Eaton, J. W., & Yaddanapudi, K. (2021) · Vaccines · doi:10.3390/vaccines9060668 · Cited by 74
Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management
Savoia, P., Astrua, C., & Fava, P. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1129478 · Cited by 81
The Human T Cell Response to Melanoma Antigens
Romero, P. J., Cerottini, J., & Speiser, D. E. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)92005-7 · Cited by 74

Authors: Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., Restifo, N. P., Haworth, L. R., Levy, C., Mavroukakis, S. A., Nichol, G., Yellin, M. J., & Rosenberg, S. A.
Affiliations: National Institutes of Health (US)
ORCID: Phan, Giao Q.
Maker, Ajay V.
Robinson, Michael R.
Quezado, Martha M.
Yang, James C.
Sherry, Richard M.
Topalian, Suzanne L.
Kammula, Udai S.
Restifo, Nicholas P.
Mavroukakis, Sharon A.
Yellin, Michael J.
Rosenberg, Steven A.
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2005-09-01
Volume: 23
Issue: 25
Pages: 6043-6053
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2005.06.205
PMC: PMC1473965
OpenAlex: W2151507811
Cited by: 1,012
References: 44
Citations by year: 2026: 6 · 2025: 15 · 2024: 18 · 2023: 17 · 2022: 31 · 2021: 45 · 2020: 81 · 2019: 46 · 2018: 45 · 2017: 55 · 2016: 60 · 2015: 64 · 2014: 49 · 2013: 63 · 2012: 43
FWCI: 30.93
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (Z99 CA999999)
National Cancer Institute (Z01BC010763)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords: metastatic melanoma, anti-CTLA-4 monoclonal antibody, CTLA-4 blockade, autoimmunity, autoimmune toxicity, tumor regression, peptide vaccination, gp100, dosing regimen, immune checkpoint inhibitors, objective response rate
MeSH terms: Adult, Aged, Antigens, Differentiation, Drug Administration Schedule, Female, Humans, Immunosuppressive Agents, Injections, Intravenous, Male, Melanoma, Middle Aged, Prognosis, Skin Neoplasms, Autoimmunity, Antigens, CD, Treatment Outcome, Cancer Vaccines, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks